spacer
home > pmps > winter 2017 > look inside
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Look Inside

Any pharmaceutical or biotechnology organisation needing to shorten R&D and manufacturing timelines while also cutting costs should consider insourcing. Although traditional outsourcing models still dominate external development and manufacturing activities, the insourcing model – which first attracted attention around 2010 – is fast gaining popularity. This is due to its unparalleled ability to provide substantial cost savings and foster an environment that promotes communication, idea sharing and problem solving. Ultimately, this creates a real time intellectual think tank with increased project productivity.

Strategic Alternatives


In a survey published in March 2015, 80% of respondents reported an expectation for growing demand of outsourcing in the coming years, up from 50% just a few years ago. Some of the factors driving the adoption of outsourcing drug development manufacturing are: reduced time to market, an increase in virtual biotech models and big pharma’s shift away from in-house R&D activities. Rising operational costs associated with drug development and manufacturing have also driven this increase. However, controls placed on healthcare costs have forced companies to look at different ways to bring products to market and streamline internal operations. As a result, creative alternatives to in-house approaches are being considered more as part of pharma and biotech organisations’ core strategies now.

From the R&D side, the pressure to increase success rates is driving companies to look at combinations of what have traditionally been internal efforts combined with external resources. In addition, the outsourcing of biopharmaceutical manufacturing has been growing to the point where it has become a common strategic decision for developers. This goes well beyond what had been used in the past, for non-core activities to now include high-value and complex technical services.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael P Trova PhDis Senior Vice President of Drug Discovery at AMRI, and responsible for leadership of the AMRI Global Discovery Services business. His current responsibilities include management of AMRI Discovery Services in India, Singapore, the UK and the US. Michael is responsible for technical leadership and personnel development of his teams, as well as customer relationship development and discovery sales. He received his BS degree in Chemistry at Rensselaer Polytechnic Institute, US, followed by a PhD in Organic Chemistry from the Ohio State University, US, and postdoctoral research at the Massachusetts Institute of Technology.

Joachim Kaus is Vice President of Chemical Development and Managing Director of Germany at AMRI and is responsible for the technical leadership, development, sales and customer relationships within their global chemical development groups located in Germany, India and the US. His experience is in managing R&D, chemical and biotechnology production under current Good Manufacturing Practice for over 25 years. Joachim received his Master’s Degree in Chemical and Biotechnology Engineering from Hochschule Emden/Leer University, Germany.
spacer
Michael P Trova
spacer
spacer
spacer
Joachim Kaus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement